by Raynovich Rod | May 21, 2019 | Biopharmaceuticals, Macro
Update-2…3:15p EDT…. Mixed day-new post after close, XBI down 0.64%, IBB down 0.94%,, Dow sell-off down 0.43%. ====== Update-1 5/22… Not much follow-through from yesterday but trade-able.A horrible news week with politics, tariffs, chips and China...
by Raynovich Rod | May 17, 2019 | Biopharmaceuticals
Update-2…NASDAQ Rally triggers biotechs-XBI up 2.3% to $82.63 just above 2019 support level.Administration eased Huawei blocks because of trade concerns. Update -1 …11a EDT-Biotech Red Screen-Following NASDAQ. Risk-Off. The sell-off that started with...
by Raynovich Rod | May 12, 2019 | Biopharmaceuticals
Update-3 12:30 P EDT ASCO Rally seems too be kicking in.Green Screen! Update-2 5/15 10;45a EDT Gene therapy and mid-cap biopharma getting traction this am.XBI up 0.7% to $82.44. Update-1 5/14 3:30P EDT,Mid and small cap biotechs rally with NASDAQ, XBI up over 2%. Per...
by Raynovich Rod | May 5, 2019 | Biopharmaceuticals
Traders -look for a turnaround in small cap biopharma and medtech today. NAZ at 7890. 5/10 1:30p EDT….Well we know now that even biotech stocks are not immune to tariffs. Risk off. Major ETFS IBB at 104.5 and XBI near 84 are at intermediate support and off lows...
by Raynovich Rod | Apr 30, 2019 | Biopharmaceuticals
Biopharma Wrap-Up: Sideways to Neutral in Active Trading for Quarter Biopharma stocks ended the quarter in a snooze as investors took a wait and see attitude as earnings roll-out for large caps. The IBB was off 0.83% today to $106.42 and up 9% QTD. The XBI is still up...
by Raynovich Rod | Apr 29, 2019 | Biopharmaceuticals
Large Cap Biopharma Stocks: Performance and Valuations for 2019. In 2019 the IBB was a less risky pick for a biopharma portfolio; ABBV and BMY look good. Merck (MRK) and Vertex (VRTX) were the top winners since 1/15/18. There was a severe correction in biopharma...
by Raynovich Rod | Apr 25, 2019 | Biopharmaceuticals
Large Cap Biopharma Stocks Review Ongoing Through Q1 Earnings Small and Mid-Caps Outperform Large Caps YTD: XBI up 21 % YTD vs IBB up 8.19% QQQ up 27%. Rally emerging today on oversold condition in biotech. We will update this valuation review since the political...
by Raynovich Rod | Apr 21, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-3 XLV up from bottom at $86 to $88.63. IBB holding but more choppy at $107 level. Update-2 12p EDT-IBB flattish at $106 as earnings on large caps come in-will be reviewed at end of week. ABBV down 0.8% on Humira concerns:, profit forecast raised EPS gains...
by Raynovich Rod | Apr 15, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-2 10:45a 4/17…XBI down 3.37% to FEB support at $86. Healthcare issues are spilling over to biotech.Red screen day and all biotechs hit very hard.Drug pricing models are under scrutiny. Update-1…NASDAQ ekes out small gains but large cap biotechs...
by Raynovich Rod | Apr 7, 2019 | Biopharmaceuticals
4/11 ALERT: Need to check out reasons for biotech sell-off; could be proposed drug pricing bills and “affordability board.” See STAT News . See 4/11 chart below for XBI. Choppy pattern returns at resistance with no breakthrough highs. Biopharma stocks...
